File: //home/govancoz/mail/new/1760480984.M257860P607663.zacp120.webway.host,S=7184,W=7267
Return-Path: <info@boxpacking.gr>
Delivered-To: govancoz@zacp120.webway.host
Received: from zacp120.webway.host
by zacp120.webway.host with LMTP
id 6IcND9jO7mivRQkA8rC0kQ
(envelope-from <info@boxpacking.gr>)
for <govancoz@zacp120.webway.host>; Wed, 15 Oct 2025 00:29:44 +0200
Return-path: <info@boxpacking.gr>
Envelope-to: mike@govan.co.za
Delivery-date: Wed, 15 Oct 2025 00:29:44 +0200
Received: from static.217.135.4.185.clients.grserver.gr ([185.4.135.217]:38462 helo=bioshop.gr)
by zacp120.webway.host with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256
(Exim 4.98.2)
(envelope-from <info@boxpacking.gr>)
id 1v8nWZ-00000002dH1-1W51
for mike@govan.co.za;
Wed, 15 Oct 2025 00:29:44 +0200
Received: from ws-dip-gc02.diplomat.com.mt (c155-179.i01-7.onvol.net [212.56.155.179])
by bioshop.gr (Postfix) with ESMTPSA id 8D11C2012F2;
Sun, 12 Oct 2025 12:59:34 +0300 (EEST)
Content-Type: multipart/alternative; boundary="===============1381465719=="
MIME-Version: 1.0
Subject: Proposal for Strategic Business Collaboration.
To: Recipients <info@boxpacking.gr>
From: "Dr. Shingo Iwamoto" <info@boxpacking.gr>
Date: Sun, 12 Oct 2025 11:59:21 +0200
Reply-To: drshingoiwamotopharm1@gmail.com
X-PPP-Message-ID: <20251012095940.6835.1378@bioshop.gr>
X-PPP-Vhost: boxpacking.gr
X-Spam-Status: No, score=2.0
X-Spam-Score: 20
X-Spam-Bar: ++
X-Ham-Report: =?ISO-8859-1?Q?Spam_detection_software=2C_running_on_the_system_=22zacp120=2Ewebway?= =?ISO-8859-1?Q?=2Ehost=22=2C=0A_has_NOT_identified_this_incoming_ema?= =?ISO-8859-1?Q?il_as_spam=2E__The_original=0A_message_has_been_attac?= =?ISO-8859-1?Q?hed_to_this_so_you_can_view_it_or_label=0A_similar_fu?= =?ISO-8859-1?Q?ture_email=2E__If_you_have_any_questions=2C_see=0A_ro?= =?ISO-8859-1?Q?ot=5C=40localhost_for_details=2E=0A_Content_preview=3A_?= =?ISO-8859-1?Q?_Dear_Esteemed_Professional=2C_I_hope_this_message_fi?= =?ISO-8859-1?Q?nds_you=0A___well=2E_Nichi-Iko_Pharmaceutical_Co=2E=2C?= =?ISO-8859-1?Q?_Ltd=2E=2C_a_leading_pharmaceutical_manufacturer=0A__?= =?ISO-8859-1?Q?__based_in_Japan=2C_is_currently_seeking_a_qualified_?= =?ISO-8859-1?Q?individual_to_=5B=2E=2E=2E=5D_=0A_Content_analysis_de?= =?ISO-8859-1?Q?tails=3A___=282=2E0_points=2C_5=2E0_required=29=0A__p?= =?ISO-8859-1?Q?ts_rule_name______________description=0A_----_-------?= =?ISO-8859-1?Q?---------------_-------------------------------------?= =?ISO-8859-1?Q?-------------=0A_-0=2E0_SPF=5FHELO=5FPASS__________SP?= =?ISO-8859-1?Q?F=3A_HELO_matches_SPF_record=0A_-0=2E0_SPF=5FPASS____?= =?ISO-8859-1?Q?___________SPF=3A_sender_matches_SPF_record=0A__0=2E2?= =?ISO-8859-1?Q?_FREEMAIL=5FREPLYTO=5FEND=5FDIGIT_Reply-To_freemail_u?= =?ISO-8859-1?Q?sername_ends_in_digit=0A_____________________________?= =?ISO-8859-1?Q?=5Bdrshingoiwamotopharm1=28at=29gmail=2Ecom=5D=0A__0=2E0?= =?ISO-8859-1?Q?_RCVD=5FIN=5FVALIDITY=5FRPBL=5FBLOCKED_RBL=3A_ADMINIS?= =?ISO-8859-1?Q?TRATOR_NOTICE=3A_The_query_to=0A_____________________?= =?ISO-8859-1?Q?_________Validity_was_blocked=2E__See=0A_____________?= =?ISO-8859-1?Q?________________https=3A//knowledge=2Evalidity=2Ecom/?= =?ISO-8859-1?Q?hc/en-us/articles/20961730681243=0A__________________?= =?ISO-8859-1?Q?____________for_more_information=2E=0A_______________?= =?ISO-8859-1?Q?______________=5B185=2E4=2E135=2E217_listed_in_bl=2Es?= =?ISO-8859-1?Q?core=2Esenderscore=2Ecom=5D=0A__0=2E0_RCVD=5FIN=5FVAL?= =?ISO-8859-1?Q?IDITY=5FSAFE=5FBLOCKED_RBL=3A_ADMINISTRATOR_NOTICE=3A_?= =?ISO-8859-1?Q?The_query_to=0A______________________________Validity?= =?ISO-8859-1?Q?_was_blocked=2E__See=0A_____________________________h?= =?ISO-8859-1?Q?ttps=3A//knowledge=2Evalidity=2Ecom/hc/en-us/articles?= =?ISO-8859-1?Q?/20961730681243=0A______________________________for_m?= =?ISO-8859-1?Q?ore_information=2E=0A_____________________________=5B1?= =?ISO-8859-1?Q?85=2E4=2E135=2E217_listed_in_sa-accredit=2Ehabeas=2Ec?= =?ISO-8859-1?Q?om=5D=0A__0=2E0_RCVD=5FIN=5FVALIDITY=5FCERTIFIED=5FBL?= =?ISO-8859-1?Q?OCKED_RBL=3A_ADMINISTRATOR_NOTICE=3A_The=0A__________?= =?ISO-8859-1?Q?___________________query_to_Validity_was_blocked=2E__?= =?ISO-8859-1?Q?See=0A_____________________________https=3A//knowledg?= =?ISO-8859-1?Q?e=2Evalidity=2Ecom/hc/en-us/articles/20961730681243=0A_?= =?ISO-8859-1?Q?_____________________________for_more_information=2E=0A?= =?ISO-8859-1?Q?__________________________=5B185=2E4=2E135=2E217_list?= =?ISO-8859-1?Q?ed_in_sa-trusted=2Ebondedsender=2Eorg=5D=0A__0=2E0_HT?= =?ISO-8859-1?Q?ML=5FMESSAGE___________BODY=3A_HTML_included_in_messa?= =?ISO-8859-1?Q?ge=0A__0=2E0_KAM=5FDMARC=5FSTATUS_______Test_Rule_for?= =?ISO-8859-1?Q?_DKIM_or_SPF_Failure_with_Strict=0A__________________?= =?ISO-8859-1?Q?___________Alignment=0A__1=2E8_FREEMAIL=5FFORGED=5FRE?= =?ISO-8859-1?Q?PLYTO_Freemail_in_Reply-To=2C_but_not_From?=
X-Spam-Flag: NO
You will not see this in a MIME-aware mail reader.
--===============1381465719==
Content-Type: text/plain; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
Dear Esteemed Professional,
I hope this message finds you well.
Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer =
based in Japan, is currently seeking a qualified individual to serve as our=
official representative in South Africa. This role involves managing miner=
al procurement and overseeing the establishment of our annex office in Sout=
h Africa under a five-year contractual agreement.
This is a strategic opportunity to represent a respected global brand and =
play a key role in expanding our international presence. We are offering a =
competitive compensation package along with decision-making autonomy.
If you are interested in learning more, kindly respond to this message for=
further details.
Warm regards,
Dr. Shingo Iwamoto
President & CEO
Nichi-Iko Pharmaceutical Co., Ltd.
5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan
--===============1381465719==
Content-Type: text/html; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Diso-8859-1"/></head><BODY><P>Dear Esteemed Professional,</P>
<P>I hope this message finds you well.</P>
<P>Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacture=
r based in Japan, is currently seeking a qualified individual to serve as o=
ur official representative in South Africa. This role involves managing min=
eral procurement and overseeing the establishment of our annex office in So=
uth Africa under a five-year contractual agreement.</P>
<P>This is a strategic opportunity to represent a respected global brand an=
d play a key role in expanding our international presence. We are offering =
a competitive compensation package along with decision-making autonomy.</P>
<P>If you are interested in learning more, kindly respond to this message f=
or further details.</P>
<P>Warm regards,<BR>Dr. Shingo Iwamoto<BR>President & CEO<BR>Nichi-Iko =
Pharmaceutical Co., Ltd.<BR>5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, =
Japan</P></BODY></HTML>
--===============1381465719==--